Hepatic & Cardiometabolic Endpoints Demonstrate Efficacy of Lanifibranor Across the Spectrum of NASH Biology
Time: 9:00 am
day: Conference Day 2
Details:
- Delving into the late-stage development of lanifibranor; a balanced α, β/δ and γ agonist, for the treatment of NASH
- Demonstrating efficacy on histological NASH resolution and improvement of fibrosis, cardiometabolic health, lipid and glucose metabolism, insulin resistance and systemic inflammation in the Phase 2b NATIVE study
- Correlating adiponectin, a downstream mediator of lanifibranor signaling with the broad efficacy of lanifibranor on markers of cardiometabolic health
